The phase 2b/3 OASIS-1 trial of ALY688 ophthalmic solution for the treatment of dry eye disease has completed patient enrollment, according to a press release from Allysta Pharmaceuticals.
The randomized, double-masked, vehicle-controlled study randomized 922 patients with moderate-to-severe dry eye disease based upon signs (staining) and symptoms (patient-reported outcomes) to three potential arms of treatment: ALY688 Ophthalmic Solution (0.4%), ALY688 Ophthalmic Solution (1%), or a vehicle solution.
The assigned treatment will be administered twice daily for 12 weeks.
Allysta anticipates that